An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs Citrate/heparin/taurolidine (Primary)
- Indications Catheter infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors CorMedix
- 10 Dec 2024 New trial record